Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-09-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ivgreatertreatmentplaceboactive
  Phrases that lowered it: healthyevaluate theto evaluatedisorderof age
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 10.3% (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 11.6% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 116 (lowers risk) · Sponsor's track record
• Maximum age: 17 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 8 (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 7 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 74.8% (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder NCT01878292 · started 2013 · scored riskier than 7% of active trials completed
• A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder NCT02436239 · started 2015 · scored riskier than 8% of active trials completed
• Double-Blind Treatment of Major Depressive Disorder With Vilazodone NCT01742832 · started 2013 · scored riskier than 18% of active trials completed
• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder NCT02431806 · started 2015 · scored riskier than 10% of active trials completed
• Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone NCT02015546 · started 2012 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.